

Quorex Pharmaceuticals (San Diego, CA, USA) has announced **Thomas A. Bologna** as its president and CEO. Previously, he served as chairman, president and CEO of Ostex International, president and CEO of Scriptgen Pharmaceuticals, and chairman, president and CEO of Gen-Probe.

Lynn Butler has been appointed CEO of Sirenade Pharmaceuticals (Martinsried, Germany). Dr. Butler was formerly the director of Swentibold, vice president of strategic partnering and licensing at BASF Pharma, and licensing manager of global business development at Glaxo Wellcome. Interim CEO **Pierfausto Seneci** has been named Sirenade's chief scientific officer.

OncoGenex Technologies (Vancouver, BC, Canada) has named **Neil Clendeninn** to its board of directors. Dr. Clendeninn most recently served as head of the clinical affairs group at Agouron Pharmaceuticals, a subsidiary of Pfizer.

Conforma Therapeutics (San Diego, CA, USA) has announced the appointment of **Robert L. De Jager** to the newly created position of vice president, clinical research and development and chief medical officer. He joins Conforma from Daiichi Pharmaceutical Corp., the US subsidiary of the Japanese pharmaceutical company. Since 1997, Dr. De Jager held increasingly senior leadership positions at Daiichi, most recently as vice president, R&D, oncology and internal medicine.

Arcadia Biosciences (Davis, CA, USA) has announced that **Don Emlay** has joined the company as director of regulatory affairs and compliance. Mr. Emlay previously served as vice president of regulatory affairs with Calgene, and has more than 30 years of regulatory experience with consumer, industrial and biotechnology-based plant products.



ArQule (Woburn, MA, USA) has appointed **Dennis France** as vice president of oncology lead discovery, and **Shi-Chung Ng** as vice president of drug discovery biology. Dr. France joins the company from Novartis, where he was an executive director in oncology, and Dr. Ng was previously a senior group leader in oncology at Abbott Laboratories.

The Massachusetts Biotechnology Council (Boston, MA, USA) has named **Thomas Finneran**

as its next president, succeeding Janice Bourque who announced her resignation in February. Mr. Finneran is the Speaker of the House for the Massachusetts legislature. He has been a member of the commonwealth's House of Representatives since 1979 and was first elected Speaker in 1996.

Amgen (Thousand Oaks, CA, USA) has named **Rolf Hoffmann** to the position of senior vice president, Amgen Europe. Mr. Hoffmann joins the company from Eli Lilly & Company, where he served as area director, Latin America, president, InterAmerica, and general manager, Germany.

Invitrogen (Carlsbad, CA, USA) has named **David Hoffmeister** as senior vice president and CFO. Mr. Hoffmeister has spent 20 years at McKinsey & Company, most recently serving as a senior partner. He succeeds **C. Eric Winzer**, who will remain part of the Invitrogen executive team leading the implementation of a new enterprise resource planning system.

Brian E. Huber has joined Adherex Technologies (Research Triangle Park, NC, USA) as CSO. Dr. Huber served most recently as vice president of biology/pharmacology in drug discovery for GlaxoSmithKline.

Human Genome Sciences (Rockville, MD, USA) has named **Argeris (Jerry) N. Karabelas** chairman of the company's board of directors following the retirement of **William A. Haseltine**. The company also announced that **Craig A. Rosen** has been promoted to president and COO. Dr. Karabelas, a partner at Care Capital LLC and former CEO of worldwide pharmaceuticals for Novartis, became a director in 2002. Dr. Rosen has served as president, R&D since 1992.

Yves Ribeill has been named as a board member for Entomed (Strasbourg, France). Dr. Ribeill is cofounder and CEO of Scynexis.

Gautam Shah has been appointed Achillion Pharmaceuticals' (New Haven, CT, USA) vice president, regulatory affairs. Dr. Shah previously served as senior director of regulatory affairs at Sepracor, and as the FDA liaison in the Bayer Health Care regulatory affairs group.

Craig R. Smith, chairman, president and CEO of Guilford Pharmaceuticals, has joined the board of directors of La Jolla Pharmaceutical (San Diego, CA, USA). Dr. Smith has been with Guilford since its inception over a decade ago. La Jolla's board will increase to six members with this addition.